跳至主要內容

新聞與行事曆

新聞: 截至 2026-10-12
這些標記是什麼意思

重要性是模型對已發布報導給出的 1–5 分,不是對市場的預測。

已排定事件列上的影響是公司顯著度層級(高/中由圖譜中心度與規模判定;低僅用於人工整理的次要事件),不是對波動幅度的預測。

標記為已確認的財報日期,是 Yahoo Finance 認定由公司確認的;預估表示尚未公布。未加標記的列沒有可查的出處記錄。

經濟數據發布屬於總體經濟、不歸屬任何產業,因此在任何檢視下都會保留。沒有數值的發布表示尚未公布,頁面會直說,而不是顯示為零。

涵蓋被追蹤公司的即將到來的事件;已過去的事件會歸檔,並在可得時補上結果——這些結果都經人工整理並附引用,絕不杜撰。沒有結果的歷史列會顯示「結果待定」。

閉鎖期屆滿或指數調整的列會多出一行算術——將變得可賣出的股數,或指數基金必須買進的股數,以佔流通股的比例表示——依招股說明書或指數編製方法讀出,兩個數字都在該列註明出處。它陳述的是機制,不是價格走勢。由 IPO + 180 天推算出的閉鎖期日期會一直標為預估,直到公司自己說明為止。

未來

已排定 · 今天與明天 · 行事曆更新於 2026-10-12

10月12日週一 · 今天

10月13日週二

過往

已發布 · 最新在前

9月11日週五

財報

13:31
24/7 Wall St.

Oracle surges 7% as AI cloud backlog hits $664B

Oracle's earnings report disclosed AI cloud backlog (remaining performance obligations) of $664 billion, sending the stock up about 7%. Neocloud peers including CoreWeave rose roughly 4% on the read-through to AI infrastructure demand.

文章預覽

Investing Oracle Surges 7% as AI Cloud Backlog Hits $664B, CoreWeave and Nebius Climb 4% Oracle just posted a backlog figure large enough to reshape how the entire AI cloud infrastructure trade gets valued, and two GPU cloud pure-plays are already moving in sympathy before the broader market has fully processed what it means. By David Moadel Published September 11, 2026, 9:31am ET · 4 min read Market Movers desk. Editor: David Moadel . 𝕏 f ⧉ This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them. © Sun…

CoreWeaveOracle 開啟原文 ↗

融資

13:30
Stock Titan

Eli Lilly now owns all of AtaiBeckley

Eli Lilly closed its acquisition of AtaiBeckley, taking full ownership of the psychedelics-focused biotech after shareholders approved the merger earlier in the week. The deal adds a depression-treatment pipeline to Lilly's neuroscience portfolio.

Eli Lilly and Company 開啟原文 ↗

產品

13:00
Fierce Biotech

Is Moderna, Merck's mRNA cancer vaccine win the start of a 'personalized medicine revolution'?

Moderna and Merck reported that their individualized mRNA cancer vaccine combined with Keytruda significantly improved survival in a phase 3 melanoma trial, the first late-stage win for a personalized mRNA cancer vaccine. Detailed trial data have not yet been presented at a medical meeting.

Moderna 開啟原文 ↗

產品

11:02
MarketBeat

Arista Networks sees AI demand fueling 40% growth, discloses $9.6B in supply commitments

Arista Networks said AI-driven demand supports roughly 40% growth and disclosed $9.6 billion of purchase/supply commitments to secure component capacity. The commitment figure is a direct read on how much upstream capacity Arista has locked in for AI networking gear.

文章預覽

Arista Networks Sees AI Demand Fueling 40% Growth, $9.6B in Supply Commitments Written by MarketBeat September 11, 2026 Add As Preferred Source Share Share Share This Article Link copied to clipboard. Close Image from MarketBeat Media, LLC. Key Points Arista raised its revenue outlook to 40% growth, or $12.6 billion , as AI networking demand accelerates. Executives said the current AI infrastructure cycle could continue for years across training, inference, scale-up and scale-across architectures. Purchase commitments surged to $9.6 billion from roughly $3.6 billion three quarters earlier, ref…

Arista Networks 開啟原文 ↗

人事

10:51
Reuters

Micron's Taiwan workers to get rewards worth up to 68 months of pay

Micron will pay Taiwan employees rewards worth as much as 68 months of salary, Reuters reported. The payout size reflects the profitability of its DRAM and HBM operations in the current memory upcycle.

Micron 開啟原文 ↗

原始消息流

所有到達的消息 · 7 天